Dispensing and Discontinuation of Medications with Genetic Interactions in Real-World Data

Purpose: To evaluate frequency of clinically actionable drug-gene interactions and whether presence of genetic interactions was associated with time to medication discontinuation in a cohort of US Veterans with and without HIV. Methods: Pharmacogenomic interactions (PGx) were defined as Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A interactions. Using this definition, we identified 20 most frequently dispensed medications with at least one interaction as defined by CPIC. We calculated percentage of people dispensed ≥1 CPIC level A medication. Among those recipients, we calculated the percentage of people with a CPIC level A interaction (CPIC A PGx) and compared time to discontinuation between those with/without CPIC A PGx using Bonferroni corrected Wilcoxon rank-sum tests. Results: Of 1,452 patients, 70% were Black, 6% Hispanic, 22% White, and 3% other with the mean age at 56 years. Of these, 98% (1,420/1452) had at least one CPIC A medication, including antiretrovirals, and immunosuppressants. Of those who were dispensed with CPIC A medication, 83% had CPIC A PGx. The clinical recommendations for these interactions varied from dose to medication change. Among individuals prescribed efavirenz, having a PGx was associated with shorter time to discontinuation and Tacrolimus was associated with longer time to discontinuation. The remaining 18 CPIC medications did not demonstrate a significant association with time to discontinuation. Conclusion: Many patients with CPIC A PGx are prescribed CPIC medications. We found no clear pattern of shorter time to discontinuation for those with a CPIC A PGx. Future work should explore the real-world impact of specific interactions.

Authors

Institutions

Publication Details

Published
2026-11-16
DOI
https://doi.org/10.22541/authorea.15012298/v1
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Dispensing and Discontinuation of Medications with Genetic Interactions in Real-World Data

Amy C. Justice, Christopher T. Rentsch, Kathleen A. McGinnis, Farah Kidwai‐Khan et al.
Pharmacogenetics and Drug Metabolism
preprint

Dispensing and Discontinuation of Medications with Genetic Interactions in Real-World Data

Amy C. Justice, Christopher T. Rentsch, Kathleen A. McGinnis, Farah Kidwai‐Khan, Xu Ke
preprint en

Abstract

Purpose: To evaluate frequency of clinically actionable drug-gene interactions and whether presence of genetic interactions was associated with time to medication discontinuation in a cohort of US Veterans with and without HIV. Methods: Pharmacogenomic interactions (PGx) were defined as Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A interactions. Using this definition, we identified 20 most frequently dispensed medications with at least one interaction as defined by CPIC. We calculated percentage of people dispensed ≥1 CPIC level A medication. Among those recipients, we calculated the percentage of people with a CPIC level A interaction (CPIC A PGx) and compared time to discontinuation between those with/without CPIC A PGx using Bonferroni corrected Wilcoxon rank-sum tests. Results: Of 1,452 patients, 70% were Black, 6% Hispanic, 22% White, and 3% other with the mean age at 56 years. Of these, 98% (1,420/1452) had at least one CPIC A medication, including antiretrovirals, and immunosuppressants. Of those who were dispensed with CPIC A medication, 83% had CPIC A PGx. The clinical recommendations for these interactions varied from dose to medication change. Among individuals prescribed efavirenz, having a PGx was associated with shorter time to discontinuation and Tacrolimus was associated with longer time to discontinuation. The remaining 18 CPIC medications did not demonstrate a significant association with time to discontinuation. Conclusion: Many patients with CPIC A PGx are prescribed CPIC medications. We found no clear pattern of shorter time to discontinuation for those with a CPIC A PGx. Future work should explore the real-world impact of specific interactions.

Yale University (US), VA Connecticut Healthcare System (US), London School of Hygiene & Tropical Medicine (GB)
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon